Skip to main content
. 2016 Aug 5;7(40):66182–66191. doi: 10.18632/oncotarget.11097

Figure 4. Funnel plots for relative risks of included studies in the meta-analysis.

Figure 4

A., low-grade hemorrhagic events in cancer patients treated with ramucirumab; B., high-grade hemorrhagic events in cancer patients treated with ramucirumab.